<DOC>
	<DOCNO>NCT00779233</DOCNO>
	<brief_summary>The purpose study evaluate relative bioavailability test formulation Zidovudine 300 mg tablet already market reference formulation RETROVIR Â® 300 mg tablet ( GlaxoSmithKline ) , fasted condition healthy male female adult subject .</brief_summary>
	<brief_title>Bioequivalence Study Zidovudine 300 mg Tablets , USP Under Fasting Conditions</brief_title>
	<detailed_description>A randomize , single dose , two way crossover study conduct 32 healthy , male female adult subject compare two Zidovudine 300 mg tablet formulation fast condition . In period one x 300 mg tablet administer fasting subject . Subjects receive test product one study period reference product period . The order treatment administration per dose randomization schedule . Each dose separate least 7 day interval . A total thirty two ( 32 ) subject ( 23 male 9 female ) enrol study , twenty eight ( 28 ) subject complete clinical portion study .</detailed_description>
	<mesh_term>Zidovudine</mesh_term>
	<criteria>1 . Males female , 18 65 year age , inclusive body mass index ( BMI ) range 1830 kg/m2 inclusive , measure accord Novum Standard operate Procedures 2 . Female subject child bear potential must either abstain sexual intercourse use reliable method contraception ( e.g . condom spermicide , IUD , hormonal contraceptive ) least 30 day prior dose duration study 3 . Good health determine lack clinically significant abnormality health assessment perform screen 4 . Signed date informed consent form , meet criteria current FDA regulation 1 . If female , pregnant , lactate likely become pregnant study 2 . History allergy sensitivity Zidovudine , antiviral history drug hypersensitivity intolerance , opinion investigator , would compromise safety subject study 3 . Significant history current evidence chronic infectious disease , system disorder organ dysfunction 4 . Presence gastrointestinal disease history malabsorption within last year 5 . History psychiatric disorder occur within last two year require hospitalization medication 6 . Presence medical condition require regular treatment prescription drug ( contraceptive ) 7 . Use pharmacologic agent know significantly induce inhibit drug metabolize enzyme within 30 day prior dose 8 . Receipt drug part research study within 30 day prior dose . 9 . Drug alcohol addiction require treatment past 12 month 10 . Donation significant loss whole blood ( 480 mL ) within 30 day plasma within 14 day prior dose 11 . Positive test result HIV , Hepatitis B surface antigen Hepatitis C antibody 12 . Positive test result HIV , Hepatitis B surface antigen Hepatitis C antibody 13 . Positive test result drug abuse screen 14 . Positive serum pregnancy test</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2008</verification_date>
	<keyword>Bioequivalence</keyword>
</DOC>